Schisandrin B protects rat cortical neurons against Abeta1-42-induced neurotoxicity.
In the present study, we investigated the neuroprotective effects of schisandrin B on amyloid-beta1-42-induced toxicity and its potential mechanisms in rat cortical neuron cells. Amyloid beta1-42 significantly reduced cell viability and increased apoptosis. Pretreatment with schisandrin B prior to amyloid-beta1-42 exposure significantly elevated cell viability and reduced apoptosis. The anti-apoptotic effect of schisandrin B in rat cortical neurons was mediated by up-regulation of the anti-apoptotic protein Bcl-2 and down-regulation of the pro-apoptotic protein Bax. Schisandrin B also reduced the release of mitochondrial cytochrome c into cytosol and decreased caspase-9 and caspase-3 activities. Furthermore, schisandrin B increased activities of anti-oxidant reduced glutathione and decreased production of oxidative glutathione. Taken together, these results suggest that schisandrin B protected primary cultures of rat cortical cells against amyloid-beta1-42-induced neurotoxicity through anti-apoptosis involved in a mitochondria-mediated pathway and anti-oxidant action. Schisandrin B may represent a potential treatment strategy for Alzheimer's disease.
Wang
Bin
B
Institute of Integrated Traditional Chinese and Western Medicine, Peking University First Hospital, No. 8, Xishiku Street, Xicheng District, 100034 Beijing, China.
Wang
Xue-Mei
XM
D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism*; D053453:Caspase 9 / Q000378:metabolism; D002470:Cell Survival; D002540:Cerebral Cortex / Q000166:cytology* / Q000187:drug effects*; D034242:Cyclooctanes / Q000494:pharmacology; D045304:Cytochromes c / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D017705:Lignans / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D018696:Neuroprotective Agents; D010446:Peptide Fragments / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D011083:Polycyclic Compounds / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D016229:Amyloid beta-Peptides; D034242:Cyclooctanes; D017705:Lignans; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D011083:Polycyclic Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; C075222:amyloid beta-protein (1-42); D051028:bcl-2-Associated X Protein; C015499:schizandrin B; D045304:Cytochromes c; D053148:Caspase 3; D053453:Caspase 9; D005978:Glutathione